Advertisement

Search Results for "mala-d"

Forbes List Logo
Glenmark's R&D Gamble
With Indian pharma companies willing to cash out, is Glenn Saldanha India’s best bet for a home-grown drug?
BySeema Singh
Outperformer Mr. L D Sharma
ByBrand Connect
Tata Motors' R&D Focus
ByAshish K Mishra
R&D Investments Paying Off for Biocon
BySeema Singh
(T)ax (D)ismissed at (S)ource
ByRohin Dharmakumar
Barry Salzberg: Deloitte-d to Meet You 4
ByForbes India
Barry Salzberg: Deloitte-d to Meet You 3
ByForbes India
Barry Salzberg: Deloitte-d to Meet You 2
ByForbes India
Barry Salzberg: Deloitte-d to Meet You 1
ByForbes India
Dr D. Ramesh discusses lipoprotein & heart disease
ByBrand Connect
R&D Can Bring Down Solar Manufacturing Cost
BySeema Singh
Inside Zydus Cadila's Covid-19 vaccine—ZyCov-D—play
ByManu Balachandran,Divya J Shekhar
Razorpay turns unicorn with $100 million Series D funding
ByHarichandan Arakali
...

Latest News

Photo of the day: India Art Fair kicks off in Delhi
ByForbes India
RBI likely to hold interest rates in February 6 policy meet
BySalil Panchal
Economists flag upside to India growth after US tariff deal, but hold forecasts
BySamreen Wani
Why current tech stacks will fail DPDP (And what needs to change)
ByRoshmik Saha
Non-veg milk: The bone of contention in India-US trade deal
BySamidha Jain
Graphic of the day: Tariff relief cost: $2.5 trillion
BySamreen Wani
Why India’s IT giants are worried about Anthropic’s Claude Cowork
ByNaini Thaker
India’s concert economy: Booming sales, lagging infrastructure
ByNaini Thaker,Himani Kothari
AI agents form their own social network, humans left fascinated and alarmed
ByNaini Thaker
Advertisement
Advertisement

On Everyone’s Radar

Advertisement